Literature DB >> 26313171

Discovery of Xuebijing Injection Exhibiting Protective Efficacy on Sepsis by Inhibiting the Expression of HMGB1 in Septic Rat Model Designed by Cecal Ligation and Puncture.

Shengguang Chen1, Guoxing Dai, Jiawen Hu, Aihong Rong, Jie Lv, Lijie Su, Xianzheng Wu.   

Abstract

Xuebijing (XBJ) injection is a complex traditional Chinese prescription that has been widely used to treat sepsis in China. However, its underlying mechanisms on sepsis still remain uninvestigated. In this study, 150 male Sprague Dawley rats were randomly divided into a normal control group, cecal ligation and puncture (CLP) group, CLP+XBJ group, and CLP+gibberellic acid group. Each of them contained 3 subgroups of different treatment periods (12, 24, and 48 hours after injection, respectively). The mRNA expression of HMGB1 in liver tissue of the 4 groups was calculated by the semiquantitative reverse-transcription polymerase chain reaction. The level of IL-6, IL-10, and TNF-α was determined by an enzyme-linked immunosorbent assay. Immunohistochemical analysis for HMGB1 showed the effect of XBJ on infiltration of inflammatory cells. The mRNA expression of HMGB1 in liver tissue in CLP+XBJ and CLP+gibberellic acid groups was lower than that in the CLP group. The levels of IL-6, IL-10, and TNF-α were decreased at the each monitored time point. All these results indicated that XBJ exhibits protective efficacy on sepsis by inhibiting the expression of HMGB1.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26313171     DOI: 10.1097/MJT.0000000000000296

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  8 in total

1.  Xuebijing injection alleviates cytokine-induced inflammatory liver injury in CLP-induced septic rats through induction of suppressor of cytokine signaling 1.

Authors:  Ailin Li; Jing Li; Yuhua Bao; Dingshan Yuan; Zhongwei Huang
Journal:  Exp Ther Med       Date:  2016-06-24       Impact factor: 2.447

2.  Intravenous injection of Xuebijing attenuates acute kidney injury in rats with paraquat intoxication.

Authors:  Jia-Jun Xu; Jian-Tao Zhen; Li Tang; Qing-Ming Lin
Journal:  World J Emerg Med       Date:  2017

Review 3.  High Mobility Group Proteins in Sepsis.

Authors:  Guibin Liang; Zhihui He
Journal:  Front Immunol       Date:  2022-06-02       Impact factor: 8.786

4.  Hydroxysafflor Yellow A Attenuates the Apoptosis of Peripheral Blood CD4+ T Lymphocytes in a Murine Model of Sepsis.

Authors:  Jinping Wang; Ping Wang; Shuiqing Gui; Yun Li; Runhua Chen; Renqing Zeng; Peiyan Zhao; Hanwei Wu; Zheyu Huang; Jianlong Wu
Journal:  Front Pharmacol       Date:  2017-09-06       Impact factor: 5.810

Review 5.  Severe Type of COVID-19: Pathogenesis, Warning Indicators and Treatment.

Authors:  Ke Shi; Yao Liu; Qun Zhang; Chong-Ping Ran; Jie Hou; Yi Zhang; Xian-Bo Wang
Journal:  Chin J Integr Med       Date:  2021-12-28       Impact factor: 1.978

6.  Detecting Critical Functional Ingredients Group and Mechanism of Xuebijing Injection in Treating Sepsis.

Authors:  Qi- Wu; Chuan-Hui Yin; Yi Li; Jie-Qi Cai; Han-Yun Yang; Ying-Ying Huang; Yi-Xu Zheng; Ke Xiong; Hai-Lang Yu; Ai-Ping Lu; Ke-Xin Wang; Dao-Gang Guan; Yu-Peng Chen
Journal:  Front Pharmacol       Date:  2021-12-06       Impact factor: 5.810

7.  Beneficial effect of Xuebijing against Pseudomonas aeruginosa infection in Caenorhabditis elegans.

Authors:  Le Zhang; Yuxing Wang; Chang Cao; Yike Zhu; Wei Huang; Yi Yang; Haibo Qiu; Songqiao Liu; Dayong Wang
Journal:  Front Pharmacol       Date:  2022-08-31       Impact factor: 5.988

8.  Xuebijing Injection Maintains GRP78 Expression to Prevent Candida albicans-Induced Epithelial Death in the Kidney.

Authors:  Ting Shang; Qilin Yu; Tongtong Ren; Xin-Tong Wang; Hongyan Zhu; Jia-Ming Gao; Guixiang Pan; Xiumei Gao; Yan Zhu; Yuxin Feng; Ming-Chun Li
Journal:  Front Pharmacol       Date:  2020-01-06       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.